Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients?
Author(s): Schmartz D, Tabardel Y, Preiser JC, Barvais L, d’Hollander A, Duchateau J, Vincent JL Affiliation(s): Department of Anesthesiology, Erasme University Hospital, Brussels, Belgium. denis.schmartz@ulb.ac.be Publication date & source: 2003-01, J Thorac Cardiovasc Surg., 125(1):184-90. Publication type: Clinical Trial; Randomized Controlled Trial OBJECTIVES: Aprotinin has been shown to have anti-inflammatory properties, but its effects on the inflammatory reaction to cardiopulmonary bypass remain controversial. This prospective, randomized, double-blind study evaluated the influence of aprotinin on various blood markers of inflammation during and after cardiopulmonary bypass. METHODS: Sixty male patients underwent coronary artery bypass grafting. The patients were randomized into 3 groups: a placebo group, a second group receiving 2,000,000 KIU of aprotinin followed by an infusion of 500,000 KIU/h and 2,000,000 KIU in the pump prime, and a third group receiving half this dosage.
